Management of mTOR inhibitor side effects

Clinical Journal of Oncology Nursing

Volumn 13, Issue SUPPL. 6, 2009, Pages 19-23

  Creel, Patricia A ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE; RAPAMYCIN; SIGNAL PEPTIDE; TEMSIROLIMUS;

CASE REPORT; CHEMICALLY INDUCED DISORDER; DRUG ANTAGONISM; DRUG ERUPTION; DRUG MONITORING; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; MIDDLE AGED; NURSING; ONCOLOGY NURSING; PNEUMONIA; REVIEW; STOMATITIS;

ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; DRUG ERUPTIONS; DRUG MONITORING; FEMALE; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; KIDNEY NEOPLASMS; MIDDLE AGED; ONCOLOGIC NURSING; PNEUMONIA; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SIROLIMUS; STOMATITIS;

EID: 77949517428     PISSN: 10921095     EISSN: 1538067X     Source Type: Journal    
DOI: 10.1188/09.CJON.S2.19-23     Document Type: Article

References (18)

1. Alterio, D., Jereczek-Fossa, B.A., Fiore, M.R., Piperno, G., Ansarin, M., & Orecchia, R. (2007). Cancer treatment-induced oral mucositis. Anticancer Research, 27(2), 1105-1125.
2. Bellmunt, J., Szczylik, C., Feingold, J., Strahs, A., & Berkenblit, A. (2008). Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Annals of Oncology, 19(8), 1387-1392.
3. Bukowski, R.M., & Wood, L.S. (2007). Renal cell carcinoma: State-of-theart diagnosis and treatment. Clinical Oncology News, 2(2), 1-12.
4. Cohen, H., & McGovern, F.J. (2005). Renal-cell carcinoma. New England Journal of Medicine, 353(23), 2477-2490.
5. Cupp, M.J., & Tracy, T.S. (1998). Cytochrome p450: New nomenclature and implications. American Family Physicians, 57(1), 107-116.
6. Eilers, J. (2004). Nursing interventions and supportive care for the prevention and treatment of oral mucositis associated with cancertreatment. Oncology Nursing Forum, 31(4), 13-23.
7. Hutson, T., Figlin, R., Kuhn, J., & Motzer, R.J. (2008). Targetedtherapies for metastatic renal cell carcinoma: An overviewof toxicity and dosing strategies. Oncologist, 139(10), 1084-1096.
8. Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., & Thun, M.J. (2009). Cancer statistics, 2009. CA: A Cancer Journal for Clinicians, 59(4), 225-249.
9. Mabasa, V.H., & Ensom, M.H. (2005). The role of therapeutic monitoring of everolimus in solid organ transplantation. Therapeutic Drug Monitoring, 27(5), 666-767.
10. Malizzia, L.J., & Hsu, A. (2008). Temsirolimus, an mTOR inhibitor for treatment of patients with advanced renal cell carcinoma. Clinical Journal of Oncology Nursing, 12(4), 639-646.
11. Motzer, R.J., Escudier, B., Oudard, O., Hutson, T.E., Porta, C., Bracarda, S., et al. (2008). Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled, phase III trial. Lancet, 372(9637), 449-456.
12. National Cancer Institute. (2003). Common Terminology Criteria for Adverse Events [v.3.0]. Therapy evaluation program. Retrieved January 21, 2008, from http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
13. National Comprehensive Cancer Network. (2008). Clinical Practice Guidelines in Oncology™ [v.1.09]: Kidney cancer. Retrieved December 10, 2008, from http://www.nccn.org/professionals/physician_gls/f_guidelines.asp
14. Neuhaus, P., Klupp, J., & Langrehr, J.M. (2001). mTOR inhibitors: An overview. Liver Transplantation, 7(6), 473-484.
15. Novartis Pharmaceuticals. (2009). Afinitor® [Prescribing information]. East Hanover, NJ: Author.
16. Tabernero, J., Rojo, F., Burris, H., Casado, E., Macarulla, T., Jones, S., et al. (2005). A phase I study with tumor molecular pharmacodynamic (MPD) evaluation of dose and schedule of the oral mTOR-inhibitor everolimus (RAD001) in patients (pts) with advanced solid tumors [Abstract 3007]. Retrieved November 10, 2009, from http://meeting.ascopubs.org/cgi/content/abstract/23/16_suppl/3007
17. Trubetskoy, O., Marks, B., Zielinski, T., Yueh, M.F., & Raucy, J. (2005). A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. APPS Journal, 7(1), 6-13.
18. Wyeth Pharmaceuticals. (2008). Torisel® [Prescribing information]. Madison, NJ: Author.